The presence of oligoclonal or monoclonal T cell expansion is implicated in the pathogenesis of a variety of autoimmune and neoplastic diseases. In autoimmune and neoplastic diseases. In autoimmune diseases the autoreactive T cells may be directly responsible for tissue damage or they have be indirectly responsible by providing help to autoreactive B cells to secrete autoantibodies involved in tissue damage and/or dysfunction. The ability to down modulate specific autoimmune responses or to eliminate a specific neoplastic T cell clone, therefore, would be an important advance in the therapy of these chronic illnesses. We have determined the cellular and molecular interactions involved in the regulation of the human autoreactive T and B cell responses to DNA topoisomerase I (topo I), a major autoantigen in systematic sclerosis. Our studies indicate that the Recent data concerning the functional capacity of dendritic cells (DCs) to regulate immune responses indicate that mature DC are potent antigen- presenting cells (APC) by virtue of their high constitutive expression of co-stimulatory molecules, although certain DC subsets T cell hyporesponsiveness or tolerance. In the proposed studies we will examine two approaches to the regulation of autoreactive T cells specific for topo I: first, we plan to use dendritic cells as potent antigen presenting cells to induce to TCR-specific (anti-clonotypic) regulatory T cells directed toward the autoreactive topo I-specific T cells; second, we plan to use functionally immature (i.e. tolerogenic) DCs and genetically modified DCs to directly delete (through apoptosis) or energize autoreactive T cells. These studies will investigate approaches for elimination and/or energy of the autoreactive T cells in vitro and will serve as the basis for the development of novel targeted immunosuppressive therapy for SSc, other autoimmune diseases, and malignant T cell disorders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073743-05
Application #
6591563
Study Section
Project Start
2002-05-08
Project End
2002-12-31
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Lohmueller, Jason J; Sato, Shuji; Popova, Lana et al. (2016) Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential. Sci Rep 6:31740
Zhang, Lixin; Vlad, Anda; Milcarek, Christine et al. (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423-35
Sun, Chengqun; Heid, Michelle E; Keyel, Peter A et al. (2013) The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One 8:e61886
Kimura, Takashi; McKolanis, John R; Dzubinski, Lynda A et al. (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6:18-26
Miskov-Zivanov, Natasa; Turner, Michael S; Kane, Lawrence P et al. (2013) The duration of T cell stimulation is a critical determinant of cell fate and plasticity. Sci Signal 6:ra97
Keyel, Peter A; Roth, Robyn; Yokoyama, Wayne M et al. (2013) Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation. Toxins (Basel) 5:1105-18
Keyel, Peter A; Tkacheva, Olga A; Larregina, Adriana T et al. (2012) Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189:4621-9
Cramer, Daniel W; Finn, Olivera J (2011) Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol 23:265-71
Morel, Penelope A; Turner, Michael S (2011) Dendritic cells and the maintenance of self-tolerance. Immunol Res 50:124-9

Showing the most recent 10 out of 90 publications